Posted by Michael Wonder on 22 Dec 2024
LimmaTech awarded FDA fast track designation for vaccine candidate against Staphylococcus aureus
19 December 2024 - LimmaTech Biologics announced today that the US FDA has granted fast track designation to LimmaTech’s multivalent toxoid vaccine candidate, LBT-SA7, designed to prevent skin and soft tissue infections caused by the bacterial pathogen, Staphylococcus aureus.
LBT-SA7 will be tested in a randomised, double-blinded, and controlled dose-escalation Phase 1 study at a clinical trial centre in the US, including 130 participants aged 18-50 years.
